Cardima/FDA Meeting Planned To Clarify Revelation Tx Reporting Issues
This article was originally published in The Gray Sheet
Executive Summary
Cardima is planning a September meeting with FDA to discuss perceived protocol compliance problems with the clinical trial of its Revelation Tx ablation catheter
You may also be interested in...
Cardima Seeks Suitor For Its Surgical Ablation Catheter Business By June
Cardima aims to find an acquirer for the Revelation Tx ablation catheter and all other assets by the end of Q2 to avoid conducting another financing round
Cardima Seeks Suitor For Its Surgical Ablation Catheter Business By June
Cardima aims to find an acquirer for the Revelation Tx ablation catheter and all other assets by the end of Q2 to avoid conducting another financing round
Less Invasive AF Ablation Procedures Touted By Cardima, Awaiting Revelation
Cardima will develop minimally invasive applications of its Surgical Ablation System to treat atrial fibrillation while awaiting FDA's verdict on an amended PMA for the transcatheter Revelation Tx